Abstract
The intracellular cholesterol transporter NPC1 functions in late endosomes and lysosomes to efflux unesterified cholesterol, and its deficiency causes Niemann–Pick disease Type C, an autosomal recessive lysosomal disorder characterized by progressive neurodegeneration and early death. Here, we use single-nucleus RNA-seq on the forebrain of Npc1−/− mice at P16 to identify cell types and pathways affected early in pathogenesis. Our analysis uncovers significant transcriptional changes in the oligodendrocyte lineage during developmental myelination, accompanied by diminished maturation of myelinating oligodendrocytes. We identify upregulation of genes associated with neurogenesis and synapse formation in Npc1−/− oligodendrocyte lineage cells, reflecting diminished gene silencing by H3K27me3. Npc1−/− oligodendrocyte progenitor cells reproduce impaired maturation in vitro, and this phenotype is rescued by treatment with GSK-J4, a small molecule inhibitor of H3K27 demethylases. Moreover, mobilizing stored cholesterol in Npc1−/− mice by a single administration of 2-hydroxypropyl-β-cyclodextrin at P7 rescues myelination, epigenetic marks, and oligodendrocyte gene expression. Our findings highlight an important role for NPC1 in oligodendrocyte lineage maturation and epigenetic regulation, and identify potential targets for therapeutic intervention.
Subject terms: Paediatric neurological disorders, Oligodendrocyte, Histone post-translational modifications
Niemann-Pick type C disease is characterized by deficiency of the endolysosomal cholesterol transporter NPC1. Here, the authors show in Npc1−/− mice that loss of NPC1 impairs oligodendrocyte lineage cell differentiation and developmental myelination through perturbed epigenetic regulation.
Introduction
Oligodendrocytes, the myelin-producing cells of the CNS, arise from oligodendrocyte progenitor cells (OPCs), a heterogeneous group of cells that retain some pluripotency and may have varying functions, including antigen presentation1–7. As they commit to becoming oligodendrocytes, OPCs differentiate into post-mitotic immature, or pre-myelinating, oligodendrocytes. Immature oligodendrocytes contact axons and further differentiate to become mature, myelinating oligodendrocytes. Oligodendrocyte differentiation and maturation are tightly regulated by both intrinsic and extrinsic signals8–11.
Cholesterol is rate-limiting in the formation of myelin12,13. Myelin is more cholesterol-rich than other plasma membranes, with cholesterol being its most abundant lipid14–16. Approximately 80% of the brain’s cholesterol is contained within myelin14,17. As cholesterol-rich lipoprotein particles do not cross the blood-brain barrier, most cholesterol used in myelin formation is synthesized de novo. Cholesterol synthesized by both oligodendrocytes and neighboring cells is necessary for myelination14,15,18,19. Notably, the mechanism by which cholesterol promotes myelination and its potential influence on oligodendrocyte differentiation remains poorly understood.
Cholesterol-rich lipoprotein particles enter cells through receptor-mediated endocytosis and transit to late endosomes and lysosomes. There, the NPC1 and NPC2 proteins work together to efflux unesterified cholesterol for use in cellular processes such as sterol biosynthesis and membrane integration20–23. Mutations in these proteins lead to Niemann–Pick disease Type C, a rare autosomal recessive lysosomal disorder characterized by the accumulation of unesterified cholesterol in late endosomes and lysosomes24–26. Neurons of the CNS are particularly vulnerable to this lipid trafficking defect, as progressive neurodegeneration is a cardinal feature of Niemann–Pick Type C. Accumulating evidence indicates that oligodendrocyte dysfunction also contributes to the neurological phenotype that occurs in this disorder. Individuals with Niemann–Pick Type C have myelin deficits, most prominently in the major white matter tracts of the brain, where the extent of myelin depletion positively correlates with clinical severity27–29. This is recapitulated in mice homozygous for a null allele of the Npc1 gene (Npc1−/−), where developmental hypomyelination is observed prior to neuron loss30–32. This developmental hypomyelination is seen throughout the brain but is most severe in the mouse forebrain30,32. Furthermore, deletion of Npc1 only in oligodendrocytes leads to myelin deficits, neurodegeneration, and ataxia, demonstrating a role for oligodendrocytes in Niemann–Pick Type C pathogenesis30. Interestingly, deletion of Npc1 specifically in neurons also leads to robust myelination defects, illustrating that both cell-autonomous and non-cell-autonomous pathways are involved in the hypomyelination phenotype30.
In this study, we used single-nucleus RNA sequencing and chromatin immunoprecipitation (ChIP) in combination with targeted assays to analyze the pathways underlying developmental hypomyelination in Npc1−/− mice. Because the forebrain is where hypomyelination is most severe and single-cell sequencing was performed previously on Npc1−/− mouse cerebella33, we focused our studies on the forebrain. We show that in the early postnatal period, cells in the oligodendrocyte lineage are the most affected cell types in the forebrain, undergoing striking transcriptional changes and cell death. Furthermore, we demonstrate that epigenetic dysfunction is a key contributor to oligodendrocyte dysfunction in Npc1−/− mice. Lastly, we show that these deficits in oligodendrocyte differentiation and survival are tied to the bioavailability of cholesterol. This work furthers our understanding of the role of cholesterol in regulating oligodendrocyte differentiation and provides targets for potential therapeutic intervention for the treatment of Niemann–Pick Type C.
Results
The oligodendrocyte lineage is severely affected in Npc1−/− mice during development
To identify the cell types and pathways in the brain that are most affected in early Niemann–Pick C pathogenesis, we performed single-nucleus RNA-sequencing (snRNA-seq) on the forebrain of littermate WT and Npc1−/− mice at 16 days of age (P16) using three biological replicates for each genotype. This unbiased analysis complemented our previous work, which demonstrates phenotypic changes in glia at this age, even in the absence of neuron death30. Approximately 13,000 nuclei from each mouse were sequenced at a depth of ~80,000 reads per cell. Expression patterns of previously established marker genes were used to identify cell type-specific clusters34–36 (Fig. 1A, B and Supplementary Fig. 1). Gene expression analysis revealed thousands of differentially expressed genes between WT and Npc1−/− samples (Fig. 1C). Notably, immature oligodendrocytes had 1764 differentially expressed genes, the most of any cluster (Fig. 1C and Supplementary Data 1). Our analysis separated the oligodendrocyte lineage into three main stages: proliferative oligodendrocyte progenitor cells (OPCs), post-mitotic and actively differentiating immature oligodendrocytes, and myelin-forming mature oligodendrocytes. Differential cell abundance analysis found significant decreases in immature and mature oligodendrocytes in Npc1−/− samples compared to WT, while all other cell populations were present in normal proportions (Fig. 1D and Supplementary Table 2). This is in accordance with published data showing severe hypomyelination and a lack of mature, myelin-forming oligodendrocytes in Npc1−/− mice during development30,32,37. This hypomyelination can be readily visualized by immunohistochemical staining for myelin basic protein (MBP) in the corpus callosum of P16 mice (Fig. 2A), corroborating previously published findings30,32,37. Taken together, these data indicate that the oligodendrocyte lineage is markedly impacted at an early timepoint in the Niemann–Pick C brain and highlight a particular vulnerability in immature oligodendrocytes.
To further explore the reduction of oligodendrocyte lineage cells in Npc1−/− mice, we stained for OLIG2, a transcription factor found throughout the lineage35,36. The number of OLIG2-positive cells in the corpus callosum was quantified at three ages: P6, P9, and P16. We chose these ages as they roughly correspond to sequential stages of oligodendrocyte development17,38–40. At P6, OPCs are present in large numbers and remain largely non-differentiated. At P9, active differentiation has begun and there is an increase in immature oligodendrocytes. By P16, there is peak myelination with large numbers of mature cells17,38–40. OLIG2-positive cell numbers were comparable between Npc1−/− and WT mice at P6, suggesting similar numbers of OPCs in these mice. However, by P9, Npc1−/− mice had significantly reduced numbers of OLIG2-positive cells compared to WT, and by P16, this reduction was even more pronounced (Fig. 2B). These data indicate a reduction in the number of oligodendrocyte lineage cells as they differentiate into immature and mature oligodendrocytes, a finding that is in line with the quantification of cell numbers from snRNA-seq (Fig. 1D). Correspondingly, western blot of forebrain lysates showed reductions in the oligodendrocyte lineage transcription factors OLIG2 and SOX1035,36 in Npc1−/− mice at P16, but not at P6 (Fig. 2C). We conclude that there is a gradual reduction in oligodendrocyte lineage markers in the Niemann–Pick C brain as these cells undergo differentiation. In contrast, neurofilament (NF200) levels (Fig. 2C) and neuron numbers (Fig. 1D and Supplementary Table 1) were similar between WT and Npc1−/− mice, indicating that deficits in the oligodendrocyte lineage were not secondary to neuron loss. Notably, there was no significant difference in the proliferation of oligodendrocyte lineage cells in the corpus callosum of mice at P6, P9, or P16 as assessed by staining for Ki6741 (Supplementary Fig. 2). However, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining42 revealed a significant increase in cell death in the corpus callosum of Npc1−/− mice at P9 when compared to WT. This increase in cell death was not apparent at P6 or P16 (Fig. 2D). Furthermore, we performed qRT-PCR to measure the expression of marker genes specific to OPCs (Cspg4 and Smoc1), immature oligodendrocytes (Enpp6 and Dusp15), and mature oligodendrocytes (Mbp and Plp1)34–36,43 in the forebrain of an independent cohort of mice at P16. OPC markers were expressed at similar levels in WT and Npc1−/− forebrain (Fig. 2E). However, immature and mature oligodendrocyte markers were significantly reduced in Npc1−/− mice (Fig. 2E). Taken together, these data strongly suggest that the decrease in oligodendrocyte lineage cells in the Niemann–Pick C brain is due, in part, to cell death, particularly while these cells are at an immature stage and actively differentiating. Notably, diminished numbers of OLIG2-positive cells were most robust in the forebrain, as the number of OLIG2-positive cells in the cerebellar white matter, where myelination defects are milder30,32, were comparable between WT and Npc1−/− mice (Supplementary Fig. 3).
Neuronal genes are up-regulated in Npc1−/− immature oligodendrocytes
To better understand the pathways associated with oligodendrocyte dysfunction and loss, we performed Gene Ontology (GO) analysis for biological process terms using differentially expressed genes in oligodendrocyte lineage cells from the snRNA-seq data. As expected, genes associated with myelination, axon ensheathment, and oligodendrocyte development were downregulated at each stage of the oligodendrocyte lineage (Fig. 3A, B and Supplementary Data 2). The cholesterol biosynthetic pathway, needed for myelination, was also downregulated in immature oligodendrocytes of mutant mice. Unexpectedly, genes associated with neurogenesis, ion transport, and synapse formation were upregulated in immature and mature oligodendrocytes of Niemann–Pick C mice (Fig. 3A, B and Supplementary Data 2). OPCs also show an upregulation of genes associated with neuron projection morphogenesis (Fig. 3A), suggesting that these pathways are altered early in the lineage. This conclusion is supported by the fact that of the 48 genes that are differentially expressed in OPCs, 42 are significantly altered in immature oligodendrocytes (Supplementary Data 1).
Repressive histone modifications are decreased in Npc1−/− oligodendrocytes
Neuron-associated genes are typically expressed in early OPCs but are silenced during oligodendrocyte differentiation44–46. The repressive histone modifications H3K9me3 and H3K27me3 are responsible for epigenetically silencing the expression of neuronal genes in oligodendrocyte lineage cells during normal maturation and myelination44,47. Furthermore, these histone modifications increase as oligodendrocytes differentiate and are known to play a crucial role in oligodendrocyte differentiation44,48 (Fig. 4A). Based on gene expression patterns observed in the snRNA-seq dataset, we hypothesized that broad changes in H3K9me3 and H3K27me3 were underlying the transcriptional differences found between oligodendrocyte lineage cells in WT and Npc1−/− mice. To test our hypothesis, we first stained brain sections for H3K27me3 and H3K9me3 and quantified their intensity. By co-staining for either NeuN or SOX10, we measured these histone modifications in neurons and oligodendrocyte lineage cells, respectively. We identified reduced staining intensity of both H3K27me3 and H3K9me3 in oligodendrocyte lineage cells in the corpus callosum of Npc1−/− mice compared to WT (Fig. 4B and Supplementary Fig. 4A). Notably, there was no difference in the staining intensity of either histone modification in cortical neurons of WT and Npc1−/− mice (Fig. 4B and Supplementary Fig. 4B), suggesting the occurrence of oligodendrocyte lineage-specific deficits in these repressive chromatin modifications. These deficits correlated with the severity of developmental dysmyelination, as we did not detect significant alterations in H3K27me3 in SOX10-positive cells in the cerebellar white matter (Supplementary Fig. 5).
We next assessed histone methylation in the oligodendrocyte lineage by western blot. To acutely isolate OPCs and immature oligodendrocytes from the whole brain of P16 mice, we used magnetic-activated cell sorting (MACS) with microbeads targeting either PDGFRα (expressed in early OPCs) or O4 (expressed later in OPCs and immature oligodendrocytes) (Fig. 4A)35,49,50. Npc1−/− PDGFRα-isolated OPCs showed significantly reduced H3K27me3, but not H3K9me3, compared to WT (Fig. 4C). However, O4-isolated cells showed decreases in both H3K9me3 and H3K27me3 (Fig. 4D), suggesting that the reduction of H3K27me3 may precede H3K9me3 during oligodendrocyte lineage maturation. Western blots of the flow-through cells (cells not bound by microbeads during MACS) showed no changes in H3K27me3 or H3K9me3, further reinforcing that these epigenetic deficits were oligodendrocyte lineage-specific (Fig. 4E).
We next probed our snRNA-seq dataset for potential causes of this epigenetic dysregulation. We found that the expression of Ezh2, a histone methyltransferase that catalyzes H3K27 methylation, was reduced in immature oligodendrocytes of Niemann–Pick C mice (Log2(FC) = −0.726; Supplementary Data 1). Furthermore, western blot analysis of O4-isolated cells revealed reduced levels of EZH2 in Npc1−/− cells compared to WT (Fig. 4F). This EZH2 reduction and the early appearance of an observable decrease in H3K27me3 led us to focus on H3K27me3 for further investigations.
Epigenetic dysregulation at neuronal genes in Npc1−/− cells
ChIP-seq and parallel bulk RNA-seq were performed on O4-purified cells from WT and Npc1−/− mouse whole brain to identify genes directly impacted by differential epigenetic regulation. ChIP was conducted for H3K27me3 and H3K27 acetylation (H3K27ac). Npc1−/− cells had a broad decrease in H3K27me3 across promoter regions (Fig. 5A). Pairing this with RNA-seq data, we identified 66 genes with both a notable decrease in H3K27me3 (Log2(FC) < −0.3) in their promoter regions and significantly increased gene expression (adjusted p < 0.05) (Fig. 5B). GO Term: Cellular Component analysis of these genes revealed three significant terms – “dendrite”, “dendritic tree”, and “neuron projection” (Fig. 5C). This enrichment was attributable to 16 genes related to neuron projections and synapse formation (Supplementary Table 2), in line with our hypothesis that increased neuron gene expression in Npc1−/− oligodendrocyte lineage cells was a consequence of decreased H3K27me3.
Our findings were corroborated by the ChIP-seq-based identification of broad increases in H3K27ac in the promoter regions of genes from Npc1−/− cells (Fig. 5D). H3K27ac often negatively correlates with H3K27me3, leading to gene activation51,52. Correlation with RNA-seq data identified 435 genes with increased promoter region acetylation and significantly higher expression (Fig. 5E). GO Term: Cellular Component gene set enrichment analysis revealed “synapse” as a significantly enriched component in this gene list (Bonferroni-corrected p = 1.324E-4). Furthermore, 10 of the 16 up-regulated neuron-related genes with decreased promoter H3K27me3 also exhibited increased promoter H3K27ac (Fig. 5E, F and Supplementary Table 2). Taken together, these data demonstrate that many of the transcriptional changes detected in Npc1−/− oligodendrocytes, particularly the increases in neuronal gene expression, are the direct result of epigenetic dysregulation.
The histone demethylase inhibitor GSK-J4 rescues oligodendrocyte differentiation in vitro
We next sought to determine whether epigenetic differences were a cause of impaired oligodendrocyte differentiation or merely a consequence. To answer this question, primary OPCs were purified from whole brains of P6 mice using PDGFRα-targeting microbeads. To promote differentiation, these cells were grown on glass coverslips for 4 days in media containing triiodothyronine. Cultured Npc1−/− OPCs recapitulated the maturation defect identified in the intact mouse brain (Fig. 6). To target epigenetic marks, we treated OPCs with GSK-J4, a well-characterized selective inhibitor of the H3K27 demethylases KDM6A and KDM6B53. Immunocytochemistry revealed that treatment of cultured Npc1−/− OPCs with GSK-J4 increased H3K27me3 compared to control-treated cells (Fig. 6A). Correspondingly, multiple genes associated with neurogenesis that were upregulated in O4-purified cells due to diminished H3K27me3 (Fig. 5F) had reduced expression after treatment with GSK-J4 (Fig. 6B). Moreover, cells were stained for MBP as an assessment of maturation. Treatment of Npc1−/− OPCs with GSK-J4 rescued cell maturation to wild type levels (Fig. 6C). In contrast, its inactive isomer, GSK-J5, had no effect (Fig. 6C). Neither small molecule altered maturation of WT OPCs in vitro. These data indicate that altered epigenetic regulation and diminished H3K27 methylation are drivers rather than consequences of impaired oligodendrocyte lineage maturation.
The Niemann–Pick C myelination phenotype is a consequence of cholesterol mistrafficking
We sought to determine the role of intracellular lipid trafficking defects in the Npc1−/− myelination phenotype. Loss of functional NPC1 leads to the lysosomal accumulation of cholesterol plus numerous secondary lipids, including sphingomyelin and complex gangliosides54–56. To begin to assess the contribution of these secondary lipid accumulations to the hypomyelination phenotype in Npc1−/− mice, we evaluated myelination in a mouse model of Niemann–Pick type A disease. These mice are deficient in the gene encoding acid sphingomyelinase (Smpd1) and develop progressive neurodegeneration while accumulating sphingomyelin in late endosomes and lysosomes57,58. The pathogenic cascade in Smpd1−/− mice has many similarities with that in Npc1−/− mice, including the accumulation of secondary lipids, defects in autophagy, lysosomal membrane permeabilization, and cell death59,60. Individuals with acid sphingomyelinase deficiency have reduced myelin, and Smpd1−/− mice show myelin reduction by 4 weeks of age57,61. However, in contrast to Npc1−/− mice, Smpd1−/− mice did not display dysmyelination at P16 (Supplementary Fig. 6), suggesting that the developmental myelination defect in Npc1−/− mice results from disruptions in intracellular cholesterol trafficking rather than from sphingolipid accumulation or lysosomal perturbations.
To directly test if mobilizing intracellular cholesterol improves developmental myelination, we treated Npc1−/− mice with a single intraperitoneal (i.p.) administration of 2-hydroxypropyl-β-cyclodextrin (HPβCD) at P7. HPβCD mobilizes stored cholesterol in NPC1 deficient cells, and a single i.p. administration of HPβCD during development significantly extends the lifespan of NPC1 deficient mice62,63. Brains from treated mice were collected at P16 and assessed for myelination. Immunohistochemical imaging showed a widespread increase in MBP staining in Npc1−/− mice treated with HPβCD compared to those receiving vehicle alone (Fig. 7A). Additionally, HPβCD significantly rescued the loss of OLIG2-positive cells in the corpus callosum of Npc1−/− mice, suggesting improved cell survival (Fig. 7B). MBP, OLIG2, and SOX10 protein levels increased in Niemann–Pick C mouse forebrains treated with HPβCD compared to those treated with vehicle (Fig. 7C), further supporting the conclusion that HPβCD improved oligodendrocyte cell lineage survival, maturation, and myelination. Correspondingly, qRT-PCR showed that HPβCD partially restored the expression of myelin genes in the forebrain, indicative of an increase in cell differentiation (Supplementary Fig. 7A). Interestingly, improvements in myelination occurred without increased expression of OPC and immature oligodendrocyte marker genes (Supplementary Fig. 7A). Analysis of electron micrographs of the corpus callosum showed that the myelin g-ratio in Npc1−/− mice was significantly increased compared to WT, signifying thinner myelin sheaths (Fig. 7D). This defect was partially rescued by HPβCD (Fig. 7D). The density of myelinated axons was also significantly diminished in the Npc1−/− corpus callosum compared to WT (Fig. 7D and Supplementary Fig. 7B). Although there was a trend toward the rescue of this metric by HPβCD, statistical significance was not reached (Supplementary Fig. 7B). Notably, treatment with HPβCD significantly increased H3K27me3 staining of SOX10-positive cells in the corpus callosum (Fig. 7E). This was associated with the rescue of neuronal genes that were found to be epigenetically dysregulated in Npc1−/− oligodendrocyte lineage cells (Fig. 7F). Together, these data demonstrate that correcting cholesterol homeostasis is sufficient to improve oligodendrocyte lineage epigenetic regulation, differentiation, and myelination in Npc1−/− mice.
H3K27me3 defects occur in a cell-autonomous manner
Because hypomyelination occurs after Npc1 deletion in either oligodendrocytes or neurons30, we sought to determine if the deficits characterized above occur due to cell-autonomous or non-autonomous pathways. To accomplish this, we used mice with a conditional null allele of Npc164. Npc1 flox/flox mice were crossed with mice heterozygous for an Npc1 null allele (Npc1+/−) and expressing Cre recombinase under the control of the Olig2 (oligodendrocyte lineage-specific) or Syn1 (neuron-specific) promoter. This cross generated experimental (Cre+; Npc1 flox/−) and littermate control mice (Cre+; Npc1 flox/+). Both Olig2-Cre; Npc1 flox/− and Syn1-Cre; Npc1 flox/− mice had reduced density of OLIG2-positive cells in the corpus callosum compared to controls (Supplementary Fig. 8), consistent with established myelination defects.
We next explored if the deficit in H3K27me3 resulted from cell-intrinsic defects or defective neuron-glial interaction. Midline brain sections from P16 mice were co-stained for H3K27me3 and SOX10. SOX10-positive cells in the corpus callosum of Olig2-Cre; Npc1 flox/− mice had significantly reduced levels of H3K27me3 compared to control mice (Fig. 8A). In contrast, there was no difference in H3K27me3 staining intensity in SOX10-positive cells from Syn1-Cre; Npc1 flox/− mice compared to controls (Fig. 8B), indicating that this epigenetic defect occurred in a cell-autonomous manner.
Finally, we treated Olig2-Cre; Npc1 flox/− mice with HPβCD at P7 to determine if HPβCD acts directly on oligodendrocytes to improve H3K27me3. At P16, Olig2-Cre; Npc1 flox/− mice treated with HPβCD demonstrated rescue of MBP staining (Fig. 8C), increased OLIG2-positive cells in the corpus callosum (Fig. 8D), and increased intensity of H3K27me3 staining in SOX10-positive cells compared to vehicle-treated controls (Fig. 8E). Together, these data show that HPβCD acts directly on oligodendrocytes to correct H3K27me3 deficits.
Discussion
Here, we identify cell types that are affected early in the Npc1−/− mouse brain and gain insights into the pathogenesis of Niemann–Pick Disease type C. We demonstrate striking changes in oligodendrocyte lineage cells that appear as animals age from P6–P16, a period of developmental myelination. While the Npc1−/− oligodendrocyte lineage appears similar to WT at P6, a timepoint that precedes myelin formation, significantly reduced numbers of OLIG2-positive cells are present by P9 as a result of cell death. We suggest that this cell death is the result of stalled differentiation and maturation, as previous studies have shown that during development, oligodendrocytes that do not form myelin undergo cell death38. Defects in the oligodendrocyte lineage culminate at P16 in a phenotype characterized by robust alterations in gene expression, diminished numbers of immature and myelinating oligodendrocytes, and a loss of myelin proteins. These data indicate an essential role for the cholesterol transport protein NPC1 in normal oligodendrocyte lineage maturation, observations that complement prior studies demonstrating the importance of cholesterol bioavailability as rate-limiting for developmental myelination12,13. However, how cholesterol impacts oligodendrocyte differentiation and myelination has remained poorly understood.
Unanticipated insights into this process and the role of NPC1 in oligodendrocyte maturation come from the analysis of snRNA-seq data, which demonstrate the significant upregulation of genes associated with neurogenesis, ion transport, and synapse formation in Npc1−/− oligodendrocyte lineage cells. These genes are typically silenced as a requisite step in oligodendrocyte lineage maturation by the repressive epigenetic marks H3K9me3 and H3K27me344. These marks are selectively lost in the Npc1−/− oligodendrocyte lineage but not in other cell types. Here, we have focused on the deficit in H3K27me3, as it appeared prior to the reduction in H3K9me3 and may be upstream. The transcriptional abnormalities we detected are seen in OPCs and immature oligodendrocytes as well as myelinating oligodendrocytes. This is noteworthy as recent studies demonstrate that cholesterol homeostasis plays an important role beyond oligodendrocyte development and impacts myelin maintenance into adulthood65. Thus, Niemann–Pick Type C provides a notable example of a developmental and degenerative nervous system disorder characterized by histone modification defects specific to the oligodendrocyte lineage that impact myelination.
We previously demonstrated that deletion of Npc1 in either oligodendrocytes or neurons leads to dysmyelination, suggesting cell-autonomous and non-autonomous pathways contribute to the myelin phenotype30. Based on data presented here, we conclude that the H3K27me3 defect occurs in a cell-autonomous fashion, as the phenotype is present in Olig2-Cre; Npc1flox/− mice, but not in Syn1-Cre; Npc1flox/− mice. Furthermore, primary OPCs deficient in NPC1 recapitulate this maturation defect in vitro in the absence of neurons, and treatment with the histone demethylase inhibitor GSK-J4 rescues this phenotype. Notably, diminished H3K27me3 tightly correlates with the observed decrease in expression of the histone methyltransferase EZH2.
In NPC1-deficient mice, hypomyelination is severe in the forebrain but is more modest in the cerebellum, brainstem, and spinal cord30–32, suggesting that oligodendrocytes that originate from different progenitor cell pools may have varying susceptibility to a lack of exogenous cholesterol. This pattern is also seen in our data, where diminished oligodendrocyte numbers and reduced H3K27me3 are seen in the corpus callosum but not in the cerebellar white matter. Interestingly, it was recently shown that cholesterol biosynthesis is one of the main pathways distinguishing oligodendrocyte lineage cells that originate in the forebrain from those that originate in the spinal cord66. The cells in the forebrain have lower cholesterol biosynthetic enzyme expression than cells in the spinal cord. This is coupled with increased expression of proteins associated with cholesterol endocytosis in forebrain cells66. These differences in cholesterol homeostasis may contribute to the sensitivity of forebrain oligodendrocyte lineage cells to NPC1 deficiency.
Our experimental evidence supports a model in which defective intracellular cholesterol trafficking underlies impaired oligodendrocyte lineage maturation due to NPC1 deficiency. The role of cholesterol in this process is suggested by data showing that Npc1−/− but not Smpd1−/− mice exhibit dysmyelination at P16. Further evidence comes from experiments with the cholesterol-mobilizing agent HPβCD. Partial rescue of myelination defects in Npc1−/− mice is achieved by a single i.p. administration of HPβCD at P7. While this treatment is known to significantly extend the lifespan of Npc1−/− mice, the mechanism underlying this effect has been incompletely understood. We argue that the rescue of oligodendrocyte maturation significantly contributes to this beneficial effect. Treatment of Olig2-Cre; Npc1 flox/− mice with HPβCD leads to improved H3K27me3 and myelination, suggesting that HPβCD acts directly on oligodendrocytes. Notably, previously published data demonstrate that Npc1−/− mice receiving a single i.p. administration of HPβCD complexed with allopregnanolone at P7 live markedly longer than mice injected just 3 days later at P1067. This differential treatment efficacy during a narrow developmental window correlates with the timing of the peak oligodendrocyte lineage cell death in Npc1−/− mice demonstrated here.
Several mechanisms may link intracellular cholesterol trafficking defects to epigenetic dysregulation. In addition to its buildup in the lysosome, cholesterol accumulates in the mitochondria of NPC1 deficient cells, causing mitochondrial dysfunction and impaired energy metabolism68–72. The TCA metabolite α-ketoglutarate serves as a cofactor for Jumanji family of histone lysine demethylases, providing a link between metabolism and epigenetic regulation73. Additionally, acetyl-CoA, which is decreased in the brains of Npc1−/− mice, acts as an enhancer of histone deacetylase activity69,74–76 to influence gene expression. This mitochondrial dysfunction may also contribute to increased production of reactive oxygen species, as signs of increased oxidative stress have been reported in tissues from NPC1-deficient mice, as well as in human patients72,77. Additionally, cholesterol bioavailability has been shown to affect signaling cascades that influence myelination and oligodendrocyte maturation, including mTORC1 and TFEB activity as well as kinase cascades78–83; iPathway analysis of differentially expressed genes in purified O4+ cells nominates several of these as potential contributors to the phenotype of Npc1−/− mice (Supplementary Fig. 9). Future studies will be aimed at linking alterations in these pathways with the epigenetic changes and disruptions of oligodendrocyte maturation that characterize the Niemann–Pick brain.
In summary, our findings identify an important role for NPC1 in oligodendrocyte lineage maturation and developmental myelination that is manifested through the epigenetic cascade required for this process. Moreover, we demonstrate unexpected impacts of Niemann–Pick C therapeutics on this pathway and suggest that this rescue contributes to beneficial effects in Npc1−/− mice. Our data broaden the target cells in the Niemann–Pick brain that contribute to disease phenotypes and that are amenable to rescue, and they provide insights into mechanisms by which intracellular cholesterol bioavailability regulates myelination.
Methods
Antibodies
Primary antibodies
The following primary antibodies (antigen [clone], dilution, vendor, cat. no.) were used for these studies: NPC1 [EPR5209], 1:500, Abcam, ab134113; NeuN [A60], 1:500, MilliporeSigma, MAB377; Ki67 [polyclonal], 1:200, Abcam, ab15580; Vinculin [hVIN-1], 1:2000, MilliporeSigma, V9131; Neurofilament [N52], 1:500, MilliporeSigma, MAB5266; H3K27me3 [C36B11], 1:200 [IF], 1:1000 [WB], Cell Signaling Technologies, 9733 S; H3K9me3 [D4W1U], 1:200 [IF], 1:1000 [WB], Cell Signaling Technologies, 13969 S; Histone H3 [96C10], 1:2000, Cell Signaling Technologies, 3638 S; MBP12, 1:100 [IF], 1:500 [WB], Abcam, ab7349; OLIG2 [polyclonal], 1:500 [IF], 1:1000 [WB], MilliporeSigma, AB9610; SOX10 [SP267], 1:400, Abcam, ab227680; SOX10 [A-2], 1:200, Santa Cruz Biotechnology, sc-365692; H3K27me3 [polyclonal], ActiveMotif, cat. #39155; H3K27ac [polyclonal], ActiveMotif, cat. #39133.
Secondary antibodies
The following secondary antibodies (antigen, dilution, vendor, cat. no.) were used: goat anti-rabbit IgG (H + L)-HRP conjugate, 1:2000, Bio-Rad, 1706515; goat anti-mouse IgG (H + L)-HRP conjugate, 1:2000, Bio-Rad, 1706516; anti-rat IgG HRP conjugated, 1:2000, R&D Systems, HAF005; Alexa Fluor 488 goat anti-rat IgG (H + L), 1:500, Invitrogen, A11006; Alexa Fluor 594 goat anti-rat IgG (H + L), 1:500, Invitrogen, A11007; Alexa Fluor 594 goat anti-mouse IgG (H + L), 1:500, Invitrogen, A11032; Alexa Fluor 488 goat anti-rabbit IgG (H + L), 1:500, Invitrogen, A11008.
Mice
Npc1nih BALB/cJ mice were obtained from Jackson Laboratories (#003092) and backcrossed to C57BL6/J for at least 10 generations. Npc1−/− mice were generated as F1 hybrids by crossing Npc1+/− mice on BALB/cJ and C57BL6/J backgrounds. This hybrid cross allowed for the restoration of Mendelian frequency of Npc1−/− mice84. Genotyping was performed as previously described64. Smpd1−/− mice were maintained on the C57BL6/J background. Genotyping was done as described by ref. 58. Floxed-Npc164, Syn1-Cre (003966, Jackson Labs), and Olig2-Cre (025567, Jackson Labs) mice were maintained on the C57BL6/J background. Male Npc1flox/flox mice were crossed with female Cre+; Npc1+/− mice to generate experimental groups. Lox/Cre mice were genotyped as previously described64. Littermate mice were genotyped prior to use in experiments. Approximately equal numbers of male and female mice were used in these studies. All animal procedures were approved by the University of Michigan Committee on the Use and Care of Animals (PRO00010017). Mice were housed in a 12-h dark/light cycle, in a facility with an ambient temperature ranging from 20.6–23.9 °C and a humidity between 30–70%.
Purification of mouse primary OPCs by magnetic-activated cell separation (MACS)
OPCs were purified from whole mouse brains at P6 (for cell culture) or P16 (for histone extraction, western blot, and genetic analyses). OPC isolation was performed using reagents from Miltenyi Biotec (Auburn, CA) following manufacturer instructions. Briefly, mice were deeply anesthetized using ice (P6 mice) or isoflurane (P16) and their brains were removed. Brains were dissociated into single cell suspensions using the Neural Tissue Dissociation Kit (cat. 130-092-628) and gentleMACS Octo Dissociator (130-095-937). Dissociated cells were passed through a 70um cell strainer, then washed and resuspended in MACS buffer (0.5% bovine serum albumin in phosphate-buffered saline). Cells were incubated on ice with an Fc blocking reagent (130-092-575) for 10 min, followed by microbeads targeted to O4 (130-094-543) or PDGFRα (130-101-502) for 15 min. Cells were then run through LS columns (130-042-401) and washed 3X with MACS buffer. The flow through cells were pelleted and flash frozen. Purified OPCs were flushed from the column with a MACS buffer. OPCs were counted, pelleted, and either flash frozen or resuspended in media and plated for culture.
OPC culture and differentiation
Mice were anesthetized on ice and decapitated. Primary OPCs were isolated from P6 mouse brains by MACS using PDGFRα microbeads as described above. Cells were plated onto 15 mm PDL-coated cover glass at a density of 5 × 104 cells per cover glass. Cells were plated in OPC media (50 µg/mL insulin, 1% N2 supplement, 2% B27 supplement, 1% pen/strep, 0.1% BSA, 40 ng/mL FGF2, 20 ng/mL PDGF-AA in DMEM-F12) and allowed to settle on the cover glass for 3 h and media was then replaced with fresh OPC medium. After 24 h, OPC media was replaced with differentiation medium (50 µg/mL insulin, 1% N2 supplement, 2% B27 supplement, 1% pen/strep, 40 ng/mL triiodothyronine (T3) in DMEM-F12) containing either GSK-J4 (0.5 µM), GSK-J5 (0.5 µM), or DMSO. Differentiation medium was replaced every 2 days. Cells were fixed and stained after 4 days in differentiation medium.
Acid extraction of histones
Histones were extracted as described by ref. 85. Briefly, frozen cell pellets were lysed in hypotonic lysis buffer (10 mM Tris HCl pH8.0, 1 mM KCl, and 1.5 mM MgCl2, protease inhibitor and phosphatase inhibitor, Sigma-Aldrich) for 30 min. Sulfuric acid (0.4 N) was added, and samples were incubated overnight at 4 °C with rotation. Samples were centrifuged at 16,000 g for 10 min, supernatants were collected, and proteins were precipitated in 33% trichloroacetic acid. Histones were washed with acetone and resuspended in deionized water. Protein concentrations were measured with a PierceTM BCA Protein Assay Kit (Thermo Fisher 23227).
Western blot
Mice were anesthetized with isoflurane and perfused with saline before tissues were collected and flash frozen in liquid nitrogen. Tissues were homogenized and sonicated in RIPA buffer containing HALT protease-phosphatase inhibitor (Thermo Fisher 78430) and 0.625 mg /mL N-ethylmaleimide (Sigma E3876). Protein concentrations were determined by DC-protein assay (BioRad) and normalized. Proteins were separated on NuPAGE 4–12% Bis-Tris Protein Gels (Thermo Fisher NP0336BOX) and transferred to Immobilon-P PVDF (0.45-μm pore size, Merck Millipore). Immunoreactivity was detected with SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher) and an iBright (Thermo Fisher). Images were quantified on ImageJ, with band intensity being normalized to the indicated loading control.
Immunocytochemistry
Cells were washed three times with PBS and fixed with 4% PFA for 20 min at room temperature. Cells were washed 3X with PBS, permeabilized with 0.1% triton for 20 min, and then placed in blocking buffer (10% goat serum, 1% BSA in PBS) for 1 h. Cells were incubated with primary antibody in blocking buffer overnight at 4 °C. Slides were washed 3X with PBS and incubated with secondary antibody diluted in blocking buffer for 1 h at room temperature. Slides were washed 3X with PBS and mounted using Vectashield plus DAPI (Vector Laboratories).
Immunohistochemistry
For tissue preparation, mice were anesthetized with isoflurane and perfused with saline followed by 4% PFA. Tissues were isolated and post-fixed in 4% PFA overnight at 4 °C. Tissues were transferred to 30% sucrose at 4 °C for 48 h before being frozen in O.C.T. (Tissue-Trek). Sections were cut at 10 µm using a Leica CM1900 cryostat and adhered to slides. Slides were incubated in a solution of 0.1% Triton, 10% goat serum, and 1% BSA for 30 min. Slides were placed in blocking buffer (10% goat serum, 1% BSA in PBS) for an additional 30 min before incubating in primary antibody diluted in blocking buffer overnight at 4 °C. For histone stains, blocking buffer included the addition of 0.1% Triton. Slides were washed 3X in PBS and incubated with secondary antibodies diluted in a blocking buffer for 1 h at room temperature. Slides were then washed 3X with PBS and mounted with Vectashield plus DAPI (Vector Laboratories)
Microscopy
Confocal images were captured using a Nikon N-SIM + A1R microscope. Three images were quantified and averaged for each sample. For histone methylation quantifications, the intensity of histone methylation staining was only measured in cells staining positive for SOX10 or NeuN. The intensity for all cells across 3 images were averaged for each biological replicate. All quantifications were done using an unbiased pipeline in CellProfiler Analyst Software. Whole brain sagittal sections were captured and stitched together using a Zeiss Axio Imager Z1 microscope with an automated stage.
ChIP-seq
ChIP-seq was performed on O4-microbead-purified cells from P16 WT and Npc1−/− mice. Mice were anesthetized with isoflurane and decapitated. Cells were purified by MACS as described above. Cells were collected from six mice of each genotype and pooled together for one ChIP-seq run. Chromatin preparation and ChIP-Seq analysis were performed by Active Motif, Inc. using 4 µg the antibodies against H3K27me3 (ActiveMotif, cat. #39155) and H3K27ac (ActiveMotif, cat. #39133). For H3K27me3 samples, Drosophila melanogaster DNA was added as a minor fraction to standardize reactions using an antibody recognizing the Drosophila-specific histone variant H2Av.
The 75-nt sequence reads generated by Illumina sequencing were mapped to the mouse genome using the BWA algorithm with default settings. Only reads that passed the Illumina purity filter, aligned with no more than two mismatches, and mapped uniquely to the genome were used in subsequent analysis. Duplicate reads were also removed. For H3K27me3 samples, the number of test tags were normalized by the same number of Drosophila tags for each sample. For H3K27ac samples, the tag number of all samples was normalized to the number of tags present in the smallest sample. Alignments were extended in silico at their 3’-ends to a length of 200 bp, which corresponds to the average fragment length in the size-selected library, and assigned to 32-nt bins along the genome. The resulting data was stored in bigWig files. MACS286 and SICER87 were used to call peaks, and average profile for tag distributions were generated using ngsplot v2.61. Integrated Genomics Viewer (IGV, Broad Institute) was used to display H3K27me3 and H3K27ac traces from pooled bigWig files.
Bulk RNA-seq
RNA was collected from O4-microbead-purified cells using RNeasy Micro Kit (Qiagen 74004) following the manufacturer’s instructions. cDNA was prepared from 3 biological replicates from each group using NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB, E7490) and xGen Broad-range RNA Library Prep (IDT, 1009813) with xGen Normalase UDI Primers (IDT). This pool was subjected to 151 bp paired-end sequencing according to the manufacturer’s protocol (Illumina NovaSeq). BCL Convert Conversion Software v3.9.3 (Illumina) was used to generate de-multiplexed Fastq files. Raw reads were trimmed with bbduk88, and the quality of the trimmed reads was evaluated with FastQC v0.11.989 and MultiQC v1.1285. The trimmed reads were then mapped to the mouse reference genome (GRCm38) using the STAR aligner v2.7.9a90, and the quality of the alignments was evaluated with MultiQC. The alignment options were adjusted to improve the percentage of reads mapping uniquely to the reference. Next, featureCounts91 was used to assign count estimates to the genes, and MultiQC was used again to evaluate the quality of the resulting gene by sample count matrix. The dimensionality of the count matrix was reduced to two principal components with Principal Components Analysis (PCA)92.
Before running Differential Expression (DE) analysis, genes that had less than ten counts across all samples were removed. DE analysis was then performed with the DESeq2 library93 with default settings in R to determine differentially expressed genes, with the condition variable as the main factor within the design formula. The results were filtered to obtain the differentially expressed genes with an adjusted p < 0.05 and |log2(fold-change)| ≥0.1. In addition to the results table, volcano plots were constructed to quickly identify statistically significant genes with a large magnitude of change between conditions. Gene Ontology (GO) enrichment analysis was run on DE genes using Fisher’s exact test from the topGO library94 in R. iPathway analysis was performed by Advaita Corporation.
Single-nucleus RNA-seq
Mice were euthanized with isoflurane followed by decapitation. Brains were collected from three P16 mice from each genotype (WT and Npc1−/−), and the forebrain was dissected and flash frozen in liquid nitrogen. Nuclei were isolated using a protocol adapted from ref. 95. Forebrains were homogenized using a glass Dounce tissue grinder (25X with pestle A and 25X with pestle B) in 2 mL of EZ PREP buffer (Sigma NUC-101). Homogenized tissues were incubated on ice for 5 min with an additional 2 mL of EZ PREP. Nuclei were pelleted by centrifuging at 500 g for 5 min at 4 °C. Nuclei were washed with 4 mL EZ PREP and incubated on ice for an additional 5 min. Nuclei were centrifuged again and washed in 4 mL of nuclear suspension buffer (0.01% BSA, RNase inhibitor [Takara 2313 A]), followed by centrifugation for 5 min at 500 g. The nuclear pellet was resuspended in 1 mL of nuclear suspension buffer before filtering through a 35 µM cell strainer (Corning 352235) and counted. Nuclei were diluted to a final concentration of 800–1500 cells/µL. Single-nucleus libraries were generated using the 10X Chromium Controller system. Libraries were sequenced using an Illumina NovaSeq 6000.
The STARsolo aligner v2.7.9a96 was used to generate an index to the mouse reference genome (GRCm38) and to align the fastq files from each sample. The quality of the alignments was assessed with MultiQC v1.1289. After alignment, the following cell filters were applied to the resulting count matrix for each sample. Cells with minimal total UMI counts were removed with the EmptyDrops methodology97 and the nExpectedCells parameter was adjusted to 10,000 cells to increase the total number of cells retained per sample. Multiplets were identified and removed with DoubletFinder98 using the default parameters. The percentage of reads within each sample aligning to mitochondrial-encoded genes was examined employing violin plots with the ggplot2 library version 3.3.699 in R, and a consistent threshold of 0.10 was identified across samples to remove cells exhibiting high mitochondrial gene expression (Supplementary Fig. 10). Finally, genes expressing less than a total of ten UMI counts across all cells were removed. Density plots for the total UMI counts and total unique gene counts per sample were constructed to examine the effects of cell filtering (Supplementary Fig. 10).
After applying all cell and gene quality control filters, the Adaptively-thresholded Low-Rank Approximation (ALRA) algorithm100 was utilized to impute dropout events. After imputation, the Seurat v4.1.0 library101 in R was employed to run log-normalization on the matrix with a default scale factor of 10,000. The top 3000 variable features were then identified utilizing the FindVariableFeatures function in Seurat with default parameters. The ScaleData function in Seurat was used to center each gene’s expression values by subtracting the average expression and scale the gene’s expression values by dividing the centered values by their standard deviations. Both Principal Component Analysis (PCA)92 and Uniform-Manifold Approximation Projection (UMAP)102 dimensionality reduction techniques, with varying parameter specifications, were employed using the RunPCA and RunUMAP functions in Seurat before clustering. A shared nearest neighbor (SNN) graph was constructed with differing numbers of principal components using the FindNeighbors function. The FindClusters function was run to identify cell clusters with varying specifications for the resolution parameter. The cell clusters were then visualized with scatterplots for Npc1−/− and WT samples separately using the UMAP projections and ggplot2 library.
Differential expression (DE) analysis was then performed with the Seurat FindMarkers function, which employs a Wilcoxon rank-sum test103 iteratively between each cell cluster and all other cells. A dot plot was created with the ggplot2 library to view the normalized and scaled expression of previously determined cell type marker genes34–36,43 and the top three DE marker genes within each cell cluster (Fig. 1B). A heatmap was also created with ggplot2 to view the expression of the marker genes within each cell cluster (Supplementary Fig. 1). Cell type labels were assigned manually to each cluster based on the exploration of the results from the DE analysis and dot plot visualization. Following cell typing, the FindMarkers function was applied again, with the Wilcoxon rank-sum test, to run a DE analysis between Npc1−/− and WT samples within each cell type independently. Genes within each cell type were identified as being differentially expressed between conditions if they had an adjusted p < 0.05 and |log2(fold-change)| ≥0.5. Gene Ontology (GO) enrichment analysis was run on DE genes using Fisher’s exact test from the topGO library94 in R. Differential Abundance (DA) analysis was performed for each cell type cluster between the WT and Npc1−/− samples using the propeller function104 in R to identify statistically significant differences in the proportion of cell types between conditions.
TUNEL assay
Paraffin-embedded tissues were cut on a Reichert-Jung 2030 microtome into 10 μm sections and placed on Thermo Scientific Superfrost Plus microscope slides. Sections were adhered onto slides in an oven at 55–60 °C for 1 h. Samples were deparaffinized and stained using a Click-iTTM Plus TUNEL Assay Kit (Thermo Fisher C10618) following the manufacturer’s instructions. Slides were washed 3X with PBS and mounted with Vectashield plus DAPI (Vector Laboratories).
qRT-PCR
RNA was collected from cells or tissues using TRIzol® (Thermo Fisher) following the manufacturer’s instructions. RNA was converted to cDNA using the High Capacity Reverse Transcription kit (Applied Biosystems 4368814). Quantitative real-time PCR was performed in technical triplicates using 20 ng of cDNA. TaqManTM probes (Thermo Fisher) targeting mouse Sox10 (Mm00569909), Olig2 (Mm01210556), Mbp (Mm01266402), Smoc1 (Mm00491564), Plp1 (Mm01297210), Cspg4 (Mm00507257), Enpp6 (Mm00624107), Dusp15 (Mm00521352), Cpeb1 (Mm01314928_m1), Kcna6 (Mm00496625_s1), Lhfpl4 (Mm00625122_m1) and Cpsf2 (Mm00489754) were used. RT-qPCR was conducted using an ABI7900HT Sequence Detection System and relative expression was calculated by the 2^(-∆∆CT) method, with Cpsf2 being used as a control for normalization.
2-hydroxypropyl-β-cyclodextrin treatment
P7 mice were given a single i.p. injection of 2-hydroxypropyl-β-cyclodextrin (20% in saline) at a dose of 4000 mg /kg as previously described59,62. Some mice received injections of saline alone as a vehicle control. Mice were anesthetized with isoflurane and perfused with saline alone (tissues used for western blot or qRT-PCR) or saline followed by 4% PFA (tissues used for immunohistochemistry). Brains were collected from injected mice at P16 for analysis.
Electron microscopy
Mice were anesthetized with isoflurane and perfused with 0.9% normal saline followed by 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer. The corpus callosum was removed and post-fixed in perfusion solution overnight, followed by fixation in 1% osmium tetroxide solution for 1 h at room temperature. After dehydration, tissues were embedded in epoxy resin. For transmission electron microscopy, ultrathin sections were cut, and images were captured on a JEOL JEM-1400 Plus LaB6 TEM imaging system at 3000 magnification. ImageJ was used to measure the area within the inner (areain) and outer (areaout) rims of each myelin sheath. Axon caliber was derived from the areain, where caliber = 2r and areain = πr2. G-ratios were calculated as areainareaout. The g-ratios for at least 100 axons per sample were calculated.
Statistical analysis
GraphPad Prism 9.0 was used to determine significance (P < 0.05), F (F-statistic) and t (T-statistic) values. Unpaired Student’s t-test (2 tailed) and one-way or two-way ANOVA were used as indicated in the figure legends. A P value less than 0.05 was considered significant. All error bars are +/− SEM.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Supplementary information
Acknowledgements
This work was funded by the National Institutes of Health (R01 NS122746 to A.P.L.; T32 GM113900 to T.J.K.; R01 DA051913, R01 DA051908 to D.A.J.) and the Firefly Fund (to A.P.L.). We thank Mark Schultz, Siva Kumar Natarajan, Matthew Pun, and Sriram Venneti for their insightful discussions. We also thank Halle Kunkel for allowing us to use her illustrations of oligodendrocytes (Fig. 4A). Library preparation and next-generation sequencing for RNA-seq experiments were carried out by the University of Michigan Advanced Genomics Core.
This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (http://energy.gov/downloads/doe-public-access-plan).
Source data
Author contributions
Conceptualization: T.J.K., A.T., K.A.S., D.A.J., and A.P.L. Investigation: T.J.K., A.T., K.A.S., and J.M. Funding acquisition: T.J.K., D.A.J., and A.P.L. Critical reagent (Smpd1−/− mice): E.H.S. Supervision: D.A.J. and A.P.L. Writing – original draft: T.J.K., A.T., K.A.S., D.A.J., and A.P.L. Writing – review & editing: T.J.K., A.T., K.A.S., J.M., E.H.S., D.A.J., and A.P.L.
Peer review
Peer review information
Nature Communications thanks Akiko Nishiyama, Frank Pfrieger and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
Data availability
The data and materials supporting the findings of this study are available from the corresponding authors upon request. The raw ChIP-seq, snRNA-seq, and bulk RNA-seq data have been deposited in the GEO database under the series accession code GSE221610. Sequence alignment was done using the mouse reference genome GRCm38 [https://www.ncbi.nlm.nih.gov/assembly/GCF_000001635.20/]. Source data are provided with this paper.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Thaddeus J. Kunkel, Alice Townsend.
Contributor Information
Daniel A. Jacobson, Email: jacobsonda@ornl.gov
Andrew P. Lieberman, Email: liebermn@umich.edu
Supplementary information
The online version contains supplementary material available at 10.1038/s41467-023-39733-6.
References
- 1.Rowitch DH, Kriegstein AR. Developmental genetics of vertebrate glial-cell specification. Nature. 2010;468:214–222. doi: 10.1038/nature09611. [DOI] [PubMed] [Google Scholar]
- 2.Nishiyama A, Suzuki R, Zhu X. NG2 cells (polydendrocytes) in brain physiology and repair. Front. Neurosci. 2014;8:133. doi: 10.3389/fnins.2014.00133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Suzuki N, et al. Differentiation of oligodendrocyte precursor cells from Sox10-Venus mice to oligodendrocytes and astrocytes. Sci. Rep. 2017;7:14133. doi: 10.1038/s41598-017-14207-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Floriddia EM, et al. Distinct oligodendrocyte populations have spatial preference and different responses to spinal cord injury. Nat. Commun. 2020;11:5860. doi: 10.1038/s41467-020-19453-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.van Bruggen D, et al. Developmental landscape of human forebrain at a single-cell level identifies early waves of oligodendrogenesis. Dev. Cell. 2022;57:1421–1436 e1425. doi: 10.1016/j.devcel.2022.04.016. [DOI] [PubMed] [Google Scholar]
- 6.Kirby L, et al. Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat. Commun. 2019;10:3887. doi: 10.1038/s41467-019-11638-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hayashi C, Suzuki N. Heterogeneity of oligodendrocytes and their precursor cells. Adv. Exp. Med. Biol. 2019;1190:53–62. doi: 10.1007/978-981-32-9636-7_5. [DOI] [PubMed] [Google Scholar]
- 8.Zuchero JB, Barres BA. Intrinsic and extrinsic control of oligodendrocyte development. Curr. Opin. Neurobiol. 2013;23:914–920. doi: 10.1016/j.conb.2013.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hernandez M, Casaccia P. Interplay between transcriptional control and chromatin regulation in the oligodendrocyte lineage. Glia. 2015;63:1357–1375. doi: 10.1002/glia.22818. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Emery B. Regulation of oligodendrocyte differentiation and myelination. Science. 2010;330:779–782. doi: 10.1126/science.1190927. [DOI] [PubMed] [Google Scholar]
- 11.Brown TL, Verden DR. Cytoskeletal regulation of oligodendrocyte differentiation and myelination. J. Neurosci. 2017;37:7797–7799. doi: 10.1523/JNEUROSCI.1398-17.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Saher G, et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 2005;8:468–475. doi: 10.1038/nn1426. [DOI] [PubMed] [Google Scholar]
- 13.Saher G, Quintes S, Nave KA. Cholesterol: a novel regulatory role in myelin formation. Neuroscientist. 2011;17:79–93. doi: 10.1177/1073858410373835. [DOI] [PubMed] [Google Scholar]
- 14.Saher G, Stumpf SK. Cholesterol in myelin biogenesis and hypomyelinating disorders. Biochim Biophys. Acta. 2015;1851:1083–1094. doi: 10.1016/j.bbalip.2015.02.010. [DOI] [PubMed] [Google Scholar]
- 15.Morell P, Jurevics H. Origin of cholesterol in myelin. Neurochem. Res. 1996;21:463–470. doi: 10.1007/BF02527711. [DOI] [PubMed] [Google Scholar]
- 16.O’Brien JS. Stability of the myelin membrane. Science. 1965;147:1099–1107. doi: 10.1126/science.147.3662.1099. [DOI] [PubMed] [Google Scholar]
- 17.Muse ED, Jurevics H, Toews AD, Matsushima GK, Morell P. Parameters related to lipid metabolism as markers of myelination in mouse brain. J. Neurochem. 2001;76:77–86. doi: 10.1046/j.1471-4159.2001.00015.x. [DOI] [PubMed] [Google Scholar]
- 18.Lin JP, Mironova YA, Shrager P, Giger RJ. LRP1 regulates peroxisome biogenesis and cholesterol homeostasis in oligodendrocytes and is required for proper CNS myelin development and repair. Elife. 2017;6:e30498. doi: 10.7554/eLife.30498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Camargo N, et al. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 2017;15:e1002605. doi: 10.1371/journal.pbio.1002605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Infante RE, et al. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl Acad. Sci. USA. 2008;105:15287–15292. doi: 10.1073/pnas.0807328105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kwon HJ, et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell. 2009;137:1213–1224. doi: 10.1016/j.cell.2009.03.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Wang ML, et al. Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes. Cell Metab. 2010;12:166–173. doi: 10.1016/j.cmet.2010.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Schultz ML, Krus KL, Lieberman AP. Lysosome and endoplasmic reticulum quality control pathways in Niemann-Pick type C disease. Brain Res. 2016;1649:181–188. doi: 10.1016/j.brainres.2016.03.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Carstea ED, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277:228–231. doi: 10.1126/science.277.5323.228. [DOI] [PubMed] [Google Scholar]
- 25.Morris JA, et al. The genomic organization and polymorphism analysis of the human Niemann-Pick C1 gene. Biochem. Biophys. Res. Commun. 1999;261:493–498. doi: 10.1006/bbrc.1999.1070. [DOI] [PubMed] [Google Scholar]
- 26.Vanier MT, Duthel S, Rodriguez-Lafrasse C, Pentchev P, Carstea ED. Genetic heterogeneity in Niemann–Pick C disease: a study using somatic cell hybridization and linkage analysis. Am. J. Hum. Genet. 1996;58:118–125. [PMC free article] [PubMed] [Google Scholar]
- 27.Davies-Thompson J, Vavasour I, Scheel M, Rauscher A, Barton JJ. Reduced myelin water in the white matter tracts of patients with Niemann-Pick disease type C. AJNR Am. J. Neuroradiol. 2016;37:1487–1489. doi: 10.3174/ajnr.A4719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Walterfang M, et al. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. Neurology. 2010;75:49–56. doi: 10.1212/WNL.0b013e3181e6210e. [DOI] [PubMed] [Google Scholar]
- 29.Bernardo A, et al. Myelin defects in Niemann-Pick type C disease: mechanisms and possible therapeutic perspectives. Int J. Mol. Sci. 2021;22:8858. doi: 10.3390/ijms22168858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Yu T, Lieberman AP. Npc1 acting in neurons and glia is essential for the formation and maintenance of CNS myelin. PLoS Genet. 2013;9:e1003462. doi: 10.1371/journal.pgen.1003462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Weintraub H, et al. Neurological mutation characterized by dysmyelination in NCTR-Balb/C mouse with lysosomal lipid storage disease. J. Neurochem. 1985;45:665–672. doi: 10.1111/j.1471-4159.1985.tb04044.x. [DOI] [PubMed] [Google Scholar]
- 32.Takikita S, Fukuda T, Mohri I, Yagi T, Suzuki K. Perturbed myelination process of premyelinating oligodendrocyte in Niemann-Pick type C mouse. J. Neuropathol. Exp. Neurol. 2004;63:660–673. doi: 10.1093/jnen/63.6.660. [DOI] [PubMed] [Google Scholar]
- 33.Cougnoux A, et al. Single cell transcriptome analysis of Niemann-Pick disease, Type C1 cerebella. Int J. Mol. Sci. 2020;21:5368. doi: 10.3390/ijms21155368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014;34:11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Barateiro A, Fernandes A. Temporal oligodendrocyte lineage progression: in vitro models of proliferation, differentiation and myelination. Biochim Biophys. Acta. 2014;1843:1917–1929. doi: 10.1016/j.bbamcr.2014.04.018. [DOI] [PubMed] [Google Scholar]
- 36.Nishiyama A, Serwanski DR, Pfeiffer F. Many roles for oligodendrocyte precursor cells in physiology and pathology. Neuropathology. 2021;41:161–173. doi: 10.1111/neup.12732. [DOI] [PubMed] [Google Scholar]
- 37.Yang F, Feng X, Rolfs A, Luo J. Lovastatin promotes myelin formation in NPC1 mutant oligodendrocytes. J. Neurol. Sci. 2018;386:56–63. doi: 10.1016/j.jns.2018.01.015. [DOI] [PubMed] [Google Scholar]
- 38.Trapp BD, Nishiyama A, Cheng D, Macklin W. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J. Cell Biol. 1997;137:459–468. doi: 10.1083/jcb.137.2.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Carson JH, Nielson ML, Barbarese E. Developmental regulation of myelin basic protein expression in mouse brain. Dev. Biol. 1983;96:485–492. doi: 10.1016/0012-1606(83)90185-9. [DOI] [PubMed] [Google Scholar]
- 40.Spitzer SO, et al. Oligodendrocyte progenitor cells become regionally diverse and heterogeneous with age. Neuron. 2019;101:459–471.e455. doi: 10.1016/j.neuron.2018.12.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol. 2000;182:311–322. doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
- 42.Kyrylkova K, Kyryachenko S, Leid M, Kioussi C. Detection of apoptosis by TUNEL assay. Methods Mol. Biol. 2012;887:41–47. doi: 10.1007/978-1-61779-860-3_5. [DOI] [PubMed] [Google Scholar]
- 43.Muth KN, et al. The Dual-specificity phosphatase Dusp15 is regulated by Sox10 and Myrf in Myelinating Oligodendrocytes. Glia. 2016;64:2120–2132. doi: 10.1002/glia.23044. [DOI] [PubMed] [Google Scholar]
- 44.Liu J, et al. Chromatin landscape defined by repressive histone methylation during oligodendrocyte differentiation. J. Neurosci. 2015;35:352–365. doi: 10.1523/JNEUROSCI.2606-14.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ge WP, et al. Long-term potentiation of neuron-glia synapses mediated by Ca2+-permeable AMPA receptors. Science. 2006;312:1533–1537. doi: 10.1126/science.1124669. [DOI] [PubMed] [Google Scholar]
- 46.De Biase LM, Nishiyama A, Bergles DE. Excitability and synaptic communication within the oligodendrocyte lineage. J. Neurosci. 2010;30:3600–3611. doi: 10.1523/JNEUROSCI.6000-09.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Samudyata, Castelo-Branco G, Liu J. Epigenetic regulation of oligodendrocyte differentiation: From development to demyelinating disorders. Glia. 2020;68:1619–1630. doi: 10.1002/glia.23820. [DOI] [PubMed] [Google Scholar]
- 48.Wang W, et al. PRC2 acts as a critical timer that drives oligodendrocyte fate over astrocyte identity by repressing the Notch pathway. Cell Rep. 2020;32:108147. doi: 10.1016/j.celrep.2020.108147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Hughes EG, Stockton ME. Premyelinating oligodendrocytes: mechanisms underlying cell survival and integration. Front Cell Dev. Biol. 2021;9:714169. doi: 10.3389/fcell.2021.714169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Flores-Obando, R. E., Freidin, M. M. & Abrams, C. K. Rapid and Specific Immunomagnetic Isolation of Mouse Primary Oligodendrocytes. J. Vis. Exp. 10.3791/57543 (2018). [DOI] [PMC free article] [PubMed]
- 51.Creyghton MP, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA. 2010;107:21931–21936. doi: 10.1073/pnas.1016071107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Pasini D, et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 2010;38:4958–4969. doi: 10.1093/nar/gkq244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Kruidenier L, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;488:404–408. doi: 10.1038/nature11262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Newton J, Milstien S, Spiegel S. Niemann-Pick type C disease: the atypical sphingolipidosis. Adv. Biol. Regul. 2018;70:82–88. doi: 10.1016/j.jbior.2018.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Wanikawa M, Nakamura H, Emori S, Hashimoto N, Murayama T. Accumulation of sphingomyelin in Niemann-Pick disease type C cells disrupts Rab9-dependent vesicular trafficking of cholesterol. J. Cell Physiol. 2020;235:2300–2309. doi: 10.1002/jcp.29137. [DOI] [PubMed] [Google Scholar]
- 56.Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol. 2001;60:49–64. doi: 10.1093/jnen/60.1.49. [DOI] [PubMed] [Google Scholar]
- 57.Ledesma MD, Prinetti A, Sonnino S, Schuchman EH. Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice. J. Neurochem. 2011;116:779–788. doi: 10.1111/j.1471-4159.2010.07034.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Horinouchi K, et al. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet. 1995;10:288–293. doi: 10.1038/ng0795-288. [DOI] [PubMed] [Google Scholar]
- 59.Marin T, et al. c-Abl activation linked to autophagy-lysosomal dysfunction contributes to neurological impairment in Niemann-Pick type A disease. Front Cell Dev. Biol. 2022;10:844297. doi: 10.3389/fcell.2022.844297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Yanez MJ, et al. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: opportunities for shared therapeutic interventions. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165875. doi: 10.1016/j.bbadis.2020.165875. [DOI] [PubMed] [Google Scholar]
- 61.Buccinna B, et al. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A. J. Neurochem. 2009;109:105–115. doi: 10.1111/j.1471-4159.2009.05947.x. [DOI] [PubMed] [Google Scholar]
- 62.Liu B, Li H, Repa JJ, Turley SD, Dietschy JM. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J. Lipid Res. 2008;49:663–669. doi: 10.1194/jlr.M700525-JLR200. [DOI] [PubMed] [Google Scholar]
- 63.Liu B, et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl Acad. Sci. USA. 2009;106:2377–2382. doi: 10.1073/pnas.0810895106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Elrick MJ, et al. Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum. Mol. Genet. 2010;19:837–847. doi: 10.1093/hmg/ddp552. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Blanchard JW, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769–779. doi: 10.1038/s41586-022-05439-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Khandker L, et al. Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord. Cell Rep. 2022;38:110423. doi: 10.1016/j.celrep.2022.110423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 2004;10:704–711. doi: 10.1038/nm1073. [DOI] [PubMed] [Google Scholar]
- 68.Wos M, et al. Mitochondrial dysfunction in fibroblasts derived from patients with Niemann-Pick type C disease. Arch. Biochem. Biophys. 2016;593:50–59. doi: 10.1016/j.abb.2016.02.012. [DOI] [PubMed] [Google Scholar]
- 69.Kennedy BE, et al. Adaptations of energy metabolism associated with increased levels of mitochondrial cholesterol in Niemann-Pick type C1-deficient cells. J. Biol. Chem. 2014;289:16278–16289. doi: 10.1074/jbc.M114.559914. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Fernandez A, Llacuna L, Fernandez-Checa JC, Colell A. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J. Neurosci. 2009;29:6394–6405. doi: 10.1523/JNEUROSCI.4909-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Yu W, et al. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J. Biol. Chem. 2005;280:11731–11739. doi: 10.1074/jbc.M412898200. [DOI] [PubMed] [Google Scholar]
- 72.Kennedy BE, et al. Pre-symptomatic activation of antioxidant responses and alterations in glucose and pyruvate metabolism in Niemann-Pick Type C1-deficient murine brain. PLoS One. 2013;8:e82685. doi: 10.1371/journal.pone.0082685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Tran KA, Dillingham CM, Sridharan R. The role of alpha-ketoglutarate-dependent proteins in pluripotency acquisition and maintenance. J. Biol. Chem. 2019;294:5408–5419. doi: 10.1074/jbc.TM118.000831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Vogelauer M, Krall AS, McBrian MA, Li JY, Kurdistani SK. Stimulation of histone deacetylase activity by metabolites of intermediary metabolism. J. Biol. Chem. 2012;287:32006–32016. doi: 10.1074/jbc.M112.362467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Wong CC, Qian Y, Yu J. Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Oncogene. 2017;36:3359–3374. doi: 10.1038/onc.2016.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.King J, Patel M, Chandrasekaran S. Metabolism, HDACs, and HDAC inhibitors: a systems biology perspective. Metabolites. 2021;11:792. doi: 10.3390/metabo11110792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Fu R, Yanjanin NM, Bianconi S, Pavan WJ, Porter FD. Oxidative stress in Niemann-Pick disease, type C. Mol. Genet Metab. 2010;101:214–218. doi: 10.1016/j.ymgme.2010.06.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Figlia G, Gerber D, Suter U. Myelination and mTOR. Glia. 2018;66:693–707. doi: 10.1002/glia.23273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Tawk M, et al. Wnt/beta-catenin signaling is an essential and direct driver of myelin gene expression and myelinogenesis. J. Neurosci. 2011;31:3729–3742. doi: 10.1523/JNEUROSCI.4270-10.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Mathews ES, Appel B. Cholesterol biosynthesis supports myelin gene expression and axon ensheathment through modulation of P13K/Akt/mTor signaling. J. Neurosci. 2016;36:7628–7639. doi: 10.1523/JNEUROSCI.0726-16.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Sheng R, et al. Cholesterol selectively activates canonical Wnt signalling over non-canonical Wnt signalling. Nat. Commun. 2014;5:4393. doi: 10.1038/ncomms5393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Shapira KE, Ehrlich M, Henis YI. Cholesterol depletion enhances TGF-beta Smad signaling by increasing c-Jun expression through a PKR-dependent mechanism. Mol. Biol. Cell. 2018;29:2494–2507. doi: 10.1091/mbc.E18-03-0175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Chew LJ, Coley W, Cheng Y, Gallo V. Mechanisms of regulation of oligodendrocyte development by p38 mitogen-activated protein kinase. J. Neurosci. 2010;30:11011–11027. doi: 10.1523/JNEUROSCI.2546-10.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Elrick MJ, Yu T, Chung C, Lieberman AP. Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease. Hum. Mol. Genet. 2012;21:4876–4887. doi: 10.1093/hmg/dds324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat. Protoc. 2007;2:1445–1457. doi: 10.1038/nprot.2007.202. [DOI] [PubMed] [Google Scholar]
- 86.Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137. doi: 10.1186/gb-2008-9-9-r137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Zang C, et al. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics. 2009;25:1952–1958. doi: 10.1093/bioinformatics/btp340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Bushnell, B. BBMap: A Fast, Accurate, Splice-Aware Aligner. sourceforge.net/projects/bbmap/ (2014).
- 89.Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2010).
- 90.Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–930. doi: 10.1093/bioinformatics/btt656. [DOI] [PubMed] [Google Scholar]
- 92.Wold S, Esbensen K, Geladi P. Principal component analysis. Chemom. Intell. Lab. 1987;2:37–52. doi: 10.1016/0169-7439(87)80084-9. [DOI] [Google Scholar]
- 93.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Alexa, A. & Rahnenfuhrer, J. topGO: Enrichment Analysis for Gene Ontology. R Package Version 2.40.0. https://bioconductor.org/packages/topGO/ (2021).
- 95.Habib N, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods. 2017;14:955–958. doi: 10.1038/nmeth.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Benjamin Kaminow, D. Y., Alexander Dobin. STARsolo: accurate, fast and versatile mapping/quantification of single-cell and single-nucleus RNA-seq data. bioRxiv, 10.1101/2021.05.05.442755 (2021).
- 97.Lun ATL, et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 2019;20:63. doi: 10.1186/s13059-019-1662-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Systems8, 329–337.e4 (2019). [DOI] [PMC free article] [PubMed]
- 99.Wickham, H. in ggplot2: Elegant Graphics for Data Analysis (ed Wickham, H.) 189–201 (Springer International Publishing, 2016).
- 100.Linderman GC, et al. Zero-preserving imputation of single-cell RNA-seq data. Nat. Commun. 2022;13:192. doi: 10.1038/s41467-021-27729-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Hao Y, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573–3587 e3529. doi: 10.1016/j.cell.2021.04.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. ArXiv e-prints 1802.03426 (2018).
- 103.Wilcoxon, F. Critical values and probability levels for the Wilcoxon rank sum test and the Wilcoxon signed rank test. American Cyanamid (1963).
- 104.Phipson B, et al. propeller: testing for differences in cell type proportions in single cell data. Bioinformatics. 2022;38:4720–4726. doi: 10.1093/bioinformatics/btac582. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data and materials supporting the findings of this study are available from the corresponding authors upon request. The raw ChIP-seq, snRNA-seq, and bulk RNA-seq data have been deposited in the GEO database under the series accession code GSE221610. Sequence alignment was done using the mouse reference genome GRCm38 [https://www.ncbi.nlm.nih.gov/assembly/GCF_000001635.20/]. Source data are provided with this paper.